BLOOD CLOTTING FACTORS MARKET ANALYSIS

Blood Clotting Factors MarketSize and Trends

Blood Clotting Factors Market – Dynamics

Approval of novel drugs is expected to propel the market growth over the forecast period. For instance, in Janauary 2020, CSL Behring received Korea Ministry of Food and Drug Safety approval for Afstyla, a single-chain recombinant antihemophilic factor VIII therapy indicated for patients suffering from Hemophilia A. Also, in June 2019, Novo Nordisk received marketing authorization from European commission for Esperoct in the Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency). Further, in July 2019, Novo Nordisk received the Health Canada approved for Esperoct indicated for the treatment of patients with Hemophilia A.

High prevalence of Hemophilia is expected to drive the growth of the Blood Clotting Factor market. According to the data published by the Centers for Disease Control and Prevention (CDC) in September 2018, Hemophilia A affected 1 in 5,000 male births in the U.S. Similarly, according to the data published by Cleveland Clinic, in 2016, Hemophilia affected around 1 in 25,000 to 30,000 males. According to National Hemophilia Foundation 2018 report, one in 10,000 people are born with hemophilia A due to deficiency of clotting factor VIII and one in 50,000 people are born with hemophilia B due to lack of clotting factor IX

Rising initiatives and donation for supporting the patients diagnosed with Hemophilia is expected to propel the market growth over the forecast period. For instance, in April 2019, Grifols International SA a provider of plasma derived products, donated more than 100 million international units of blood clotting factor drugs under the long term initiative of providing support to the Hemophilia patients.